Update of REACH-1 and MERIT-HF clinical trials in heart failure

European Journal of Heart Failure

Volumn 1, Issue 2, 1999, Pages 197-200

  Mylona, Panayiota ^a   Cleland, John G F ^a  

^a Cardionet Editorial Office   (United Kingdom)

Author keywords

Blockers; Bosentan; Clinical trial; Endothelin antagonists; Heart failure; Metoprolol

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; METOPROLOL;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; DOUBLE-BLIND METHOD; ENDOTHELINS; EUROPE; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; METOPROLOL; MIDDLE AGED; SULFONAMIDES; SURVIVAL RATE; UNITED STATES; VENTRICULAR FUNCTION, LEFT;

EID: 0033510665     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-9842(99)00022-7     Document Type: Article

References (5)

1. Webb D.J., Strachan F.E. Am J Hypertens. 11(4 Pt 3):1998;71S-79S.
2. Cohn J.N. Beta-blockers in heart failure. Eur Heart J (Suppl). 19:1998;52-55.
3. Cleland J.G.F., Bristow M., Erdmann E., Remme W.J., Swedberg K., Waagstein F. Beta-blocking agents in heart failure. Should they be used and how? Eur Heart J. 17:1996;1629-1639.
4. Packer M. Multicentre, double-blind, placebo-controlled study of long-term endothelin blockade with bosentan in chronic heart failure - results of the REACH-1 trial (Abstract). Circulation (Suppl). 98(17):1998;I-3.
5. Rationale, design, and organisation of the metoprolol CR/XL randomised intervention trial in heart failure (MERIT-HF). Am J Cardiol. 80:1997;54J-58J.